Insider Selling: Kerry Flom Sells 6,357 Shares of Cepheid Stock (CPHD)
Cepheid (NASDAQ:CPHD) EVP Kerry Flom unloaded 6,357 shares of the stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $45.66, for a total transaction of $290,260.62. Following the sale, the executive vice president now directly owns 20,000 shares in the company, valued at approximately $913,200. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Several analysts have recently commented on the stock. Analysts at Needham & Company initiated coverage on shares of Cepheid in a research note to investors on Thursday, December 19th. They set a “hold” rating on the stock. Separately, analysts at JMP Securities initiated coverage on shares of Cepheid in a research note to investors on Wednesday, December 18th. They set a “market perform” rating on the stock. Finally, analysts at UBS AG raised their price target on shares of Cepheid from $44.00 to $48.00 in a research note to investors on Friday, December 13th. They now have a “buy” rating on the stock. Two analysts have rated the stock with a sell rating, ten have given a hold rating and ten have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $43.26.
Cepheid (NASDAQ:CPHD) traded up 0.22% during mid-day trading on Monday, hitting $45.85. 367,489 shares of the company’s stock traded hands. Cepheid has a 52-week low of $30.95 and a 52-week high of $47.21. The stock has a 50-day moving average of $45.2 and a 200-day moving average of $39.0. The company’s market cap is $3.110 billion.
Cepheid (NASDAQ:CPHD) last issued its quarterly earnings data on Thursday, October 17th. The company reported ($0.20) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.11) by $0.09. The company had revenue of $100.10 million for the quarter, compared to the consensus estimate of $93.70 million. During the same quarter last year, the company posted ($0.32) earnings per share. Cepheid’s revenue was up 25.6% compared to the same quarter last year. On average, analysts predict that Cepheid will post $-0.22 earnings per share for the current fiscal year.
Cepheid is a molecular diagnostics company that develops, manufactures and markets fully-integrated systems for testing in the Clinical market, as well as for application in its legacy Non-Clinical market.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.